Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline - Wikidata - wikimedia - TriplyDB

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

http://www.wikidata.org/entity/Q27002430

about

Risk-reducing medication for primary breast cancer: a network meta-analysis Tamoxifen Resistance: Emerging Molecular Targets Current medical treatment of estrogen receptor-positive breast cancer The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial.Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses.Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients.Long noncoding RNA linc-ITGB1 promotes cell migration and invasion in human breast cancer.Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting

P2860

Q24185817-8896C19F-C383-4B68-9D57-2EACA6EF0E07 Q26739969-9A6374EF-50C3-4867-85F0-01B244F69443 Q26795751-EC52F9F0-547E-4185-940B-4ABA2C2A4A71 Q30993896-6A0F929A-E963-4F54-AB8D-0DA169C5D020 Q37709879-874F25DB-E9F3-497C-AD4E-D9E7AB8A5AB7 Q38714539-4E681A79-2062-4426-9279-3B381F8EC482 Q38933874-414E23EB-821C-47ED-B8AD-4F3A0B374CD9 Q39022194-75760104-3A84-4D5C-AFD4-F6A9CF0CDF7C Q40280782-DED8031C-C52E-49B5-B931-BC51214886B8 Q40592257-66BAC2A7-C083-4242-9ECD-D9EB5818CFF2 Q58803015-4B4E5037-A14E-4D8A-894A-993A16362AB7

P2860

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

http://www.wikidata.org/entity/Q27002430

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@ast

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@en

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@nl

type

label

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@ast

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@en

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@nl

prefLabel

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@ast

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@en

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@nl

P1433

Q27002430-D70F8FAA-4498-4BC0-AE84-81569A1B98A3

P1476

Q27002430-4104D073-C1F0-4788-BA43-14699224C180

P2093

Q27002430-29ED5A40-8D23-479B-804B-9474A08E0584

Q27002430-58CE5DC1-EBC0-46E0-8921-91C16A0B1E39

Q27002430-5D45D6AA-F952-4DAF-9741-CF1FAB66768C

Q27002430-9170DB2D-9A71-4A8C-B0B8-37E33352F288

Q27002430-96C057BD-D096-49CE-BE10-FF5B72360B42

Q27002430-AC2CE18F-BBAA-4DD3-95E6-4AB9A48C9713

P2860

Q27002430-00F937B7-3B91-40B5-BCD6-4471853D6DDE

Q27002430-03DA783B-CBA6-4D9F-A0D1-6D48869A3FE1

Q27002430-04F28323-452B-40DD-8530-B6C85DE02E4D

Q27002430-15A6BB74-FBBE-4456-BA6C-818499122260

Q27002430-1A007014-56D4-4DEF-8197-F2C7AC11425D

Q27002430-1B6FF54B-7738-4A1B-9D08-86A92641A779

Q27002430-1C254451-C933-4413-89C1-5AF1EC4B6EA2

Q27002430-1F95ED4E-3B6A-4879-B09F-8129A47BED85

Q27002430-211D2EE4-8337-4283-B085-AC3EEFF00787

Q27002430-26879ADA-DE19-4DA5-9084-27E5346A8948

P304

Q27002430-D8E4B512-F236-452B-BF18-EA3FD3C25286

P31

Q27002430-04F5DB08-A8E2-47EE-952E-E2404E5AECAF

Q27002430-F18DF08A-FC81-4212-AB18-F4478F8A7626

P3181

Q27002430-CDB2D157-0476-48E6-B20E-CD1811F89432

P356

Q27002430-0775029C-46B6-4467-AA7E-A8C119D6DBB4

P407

Q27002430-C8F52281-76E5-4090-9E14-354DF5242F2C

P433

Q27002430-3F85C291-18F9-40F2-A1A9-9D158A7ABD00

P478

Q27002430-0DDB3D7B-0B39-43D8-A143-0769F9745433

P50

Q27002430-FB692D51-0095-4476-A124-14BF5C2A79B6

P577

Q27002430-234C70E1-6CB1-4138-8E2D-8D20922B1E71

P698

Q27002430-85885827-2152-4733-B2BC-FC025A4C74C9

P932

Q27002430-3F7F23B1-D309-47B2-82F8-C2C5111883A8

P3181

P356

P1433

Current Oncology

P1476

Adjuvant endocrine therapy for ...... rio systemic therapy guideline

@en

P2093

A Eisen

http://www.w3.org/2001/XMLSchema#string

M E Trudeau

http://www.w3.org/2001/XMLSchema#string

M Mates

http://www.w3.org/2001/XMLSchema#string

O C Freedman

http://www.w3.org/2001/XMLSchema#string

S F Dent

http://www.w3.org/2001/XMLSchema#string

S Gandhi

http://www.w3.org/2001/XMLSchema#string

P2860

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Intergroup Exemestane Study mature analysis: overall survival data.

Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

P304

S95-S113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

3979940

http://www.w3.org/2001/XMLSchema#string

P356

10.3747/CO.22.2326

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25848344

http://www.w3.org/2001/XMLSchema#string

P932

4381796

http://www.w3.org/2001/XMLSchema#string